Aromatase inhibitors for therapy of advanced breast cancer.


In postmenopausal women with advanced breast cancer, numerous phase III trials have been performed comparing the third-generation non-steroidal aromatase inhibitors (NS-AIs) anastrozole and letrozole and the steroidal AI (S-AI) exemestane in the "first-line" setting against tamoxifen and in the "second-line" setting against megestrol acetate. In both… (More)


Cite this paper

@article{Ingle2005AromataseIF, title={Aromatase inhibitors for therapy of advanced breast cancer.}, author={James N. Ingle and Vera J. Suman}, journal={The Journal of steroid biochemistry and molecular biology}, year={2005}, volume={95 1-5}, pages={113-9} }